Unlocking the Secrets of Receptor Tyrosine Kinases: Pioneering New Frontiers in Cancer Therapy

Unlocking the Secrets of Receptor Tyrosine Kinases: Pioneering New Frontiers in Cancer Therapy

At the forefront of cancer treatment, receptor tyrosine kinases (RTKs) are emerging as hotspots for research and development. These remarkable molecules, acting as "signal beacons" on the cell surface, regulate cellular growth, differentiation, and survival. However, when they malfunction, they can trigger cancer. Fortunately, scientists have developed drugs known as tyrosine kinase inhibitors (TKIs) that can precisely "repair" these signal beacons, offering new hope for cancer treatment.

Uprotein is committed to providing you with high-quality receptor tyrosine kinase proteins to support your scientific exploration. Our rigorously validated products cover a wide range of popular RTK targets, including EGFR, HER2, VEGFR, MET, PDGFR, ROR1, TRKA, DDR1, ALK, TIE1, and others. These proteins play pivotal roles in cancer treatment and serve as essential tools for researching and developing novel TKIs.

Uprotein's Validation Data

• EGFR (Epidermal Growth Factor Receptor): Overexpressed or mutated in various cancers, such as lung, breast, and colorectal cancers, EGFR-TKIs like Gefitinib and Erlotinib are widely used in clinical practice, significantly improving patient survival rates.

• 

• HER2 (Human Epidermal Growth Factor Receptor 2): Overexpressed in breast and gastric cancers, HER2 is an important therapeutic target. Trastuzumab (Herceptin) has significantly improved the prognosis of HER2-positive breast cancer patients by targeting HER2.

• 

• VEGFR2 (Vascular Endothelial Growth Factor Receptor 2): VEGFR2 plays a critical role in tumor angiogenesis. Bevacizumab effectively inhibits tumor blood supply and delays tumor growth by targeting VEGFR2.

• 

• MET (Mesenchymal-Epithelial Transition Factor): Abnormally activated in various cancers, MET is closely associated with tumor invasion and metastasis. MET inhibitors like Capmatinib have demonstrated promising anti-tumor activity.

• 

• ALK (Anaplastic Lymphoma Kinase): Rearranged or mutated in non-small cell lung cancer and other malignancies, ALK is an important therapeutic target. Crizotinib significantly improves survival rates in ALK-positive lung cancer patients by targeting ALK.

• 

• ROR1 and ROR2: Abnormally expressed in various cancers, ROR1 and ROR2 are involved in cell proliferation and survival. ROR1 inhibitors are showing promising anti-tumor potential in clinical trials.

• 

Choose Uprotein, Embark on a New Scientific Journey

Research into receptor tyrosine kinases and their inhibitors is continuously deepening, bringing new hope to cancer treatment. Uprotein provides you with high-quality RTK proteins to support your scientific exploration. Whether for fundamental research or clinical application development, Uprotein is equipped to meet your needs.

Join us in exploring the mysteries of RTKs and contributing to the fight against cancer!

Currently Available Products: